ETF Flows Change: Direxion Daily S&P Biotech Bear 1X ETF (LABS) Rises 1.09% for Nov 22

November 22, 2016 - By Adrian Mccoy   ·   0 Comments

Nov 22 is a positive day so far for Direxion Daily S&P Biotech Bear 1X ETF (NYSEARCA:LABS) as the ETF is active during the day after gaining 1.09% to hit $36.92 per share. The exchange traded fund has 6.60 million net assets and 0.72% volatility this month.

Over the course of the day 1,024 shares traded hands, as compared to an average volume of 940 over the last 30 days for Direxion Daily S&P Biotech Bear 1X ETF (NYSEARCA:LABS).

The ETF is -39.60% of its 52-Week High and 2.60% of its low, and is currently having ATR of 0.91. This year’s performance is -7.84% while this quarter’s performance is -8.88%.

The ETF’s YTD performance is 4.33%, the 1 year is NaN% and the 3 year is NaN%.

The fund’s top holdings are: S&P Biotechnology Select Industry USD for 89.80% of assets, Fidelity Institutional Go for 18.89%, S&P Biotechnology Select for 12.54%.

More notable recent Direxion Daily S&P Biotech Bear 1X Shares (NYSEARCA:LABS) news were published by: Benzinga.com which released: “Don’t Get SICK Of Healthcare ETFs And Stocks; Try This Instead” on November 15, 2016, also Etftrends.com with their article: “How to Hedge Market Turns with Inverse ETFs” published on June 29, 2016, Marketwatch.com published: “Mr. Trump Goes To Washington” on November 15, 2016. More interesting news about Direxion Daily S&P Biotech Bear 1X Shares (NYSEARCA:LABS) were released by: Benzinga.com and their article: “A New Bearish Biotech ETF And A Lazarus Act For A Couple Leveraged Funds” published on December 03, 2015 as well as Nasdaq.com‘s news article titled: “ETFs to Play as Biotech Juggles Election & Earnings” with publication date: October 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Adrian Mccoy


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>